The overtreatment or undertreatment of patients with cancer can have life-or-death implications.
Washington, DC—The combination of nivolumab plus ipilimumab improved survival compared with ipilimumab alone in patients with previously untreated advanced melanoma, according to updated results of the phase 3 CheckMate-067 clinical trial presented at the 2017 meeting of the American Association for Cancer Research. A descriptive analysis suggested that the combination was superior to nivolumab monotherapy, although that was not a prespecified end point of the study.
As new drugs are introduced into the clinic, an active area of research is the identification of biomarkers for response that would inform oncologists about which patients are likely to respond.
Abemaciclib, a cyclin-dependent kinase (CDK)4/6 inhibitor, achieved an objective response in 1 of 5 heavily pretreated patients with metastatic hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer.
Somatostatin analogs have multiple roles in the treatment of neuroendocrine tumors (NETs), including the management of symptoms of hormone hypersecretion and, more recently, slowing tumor progression.
Sensitivity to cultural context is one of the keys to successful patient education and communication. An innovative program has met with success in encouraging women of Asian-Indio descent to participate in cancer screenings.
Nurse and patient navigators from all over the country attended the Academy of Oncology Nurse & Patient Navigators (AONN+) 2017 West Coast Regional Meeting in April. The meeting provided a forum for open dialogue around navigation and survivorship care services for patients with cancer, fostered lively discussions regarding the complexities of cancer care in the rapidly growing field of navigation, and led to new ideas for the improved delivery of navigation and survivorship care services.
Obesity is about to overtake tobacco as a modifiable risk factor for cancer. Approximately 30% of cancers could be prevented by maintaining a normal weight and healthy lifestyle, according to 2 experts who spoke at the 42nd annual meeting of the Oncology Nursing Society.
When an oncology nurse becomes a patient with cancer, she has to rethink her identity, and will experience a torrent of emotional changes.
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of some hematologic malignancies. This treatment is still investigational, and none of the CAR T-cell products being studied have received FDA approval yet, but approval is expected soon.
Page 4 of 44
Results 31 - 40 of 435
Results 31 - 40 of 435